Real-world rates and sites of recurrence after neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer

Neoadjuvant chemoimmunotherapy (NAC + P) improves pathologic complete response (pCR) and survival in early-stage triple-negative breast cancer (TNBC) compared to neoadjuvant chemotherapy (NAC) alone. Real-world recurrence outcomes outside the trial setting remain unclear. This single-institution analysis compared two cohorts of patients with early-stage TNBC treated between July 2009 and April 2023: NAC + P ( n = 344) and NAC ( n = 513). Primary outcomes were local (LR), regional (RR), and distant recurrence (DR); secondary outcomes were DR sites and disease-free survival (DFS). The NAC + P cohort presented with less advanced disease at diagnosis. Overall pCR was higher in NAC + P (58% vs. 36%, p < 0.001). Two-year LR and RR rates did not differ. The 2-year DR rate was nearly halved in NAC + P (9.6% vs. 18%, p < 0.001) and remained lower among patients with residual disease (16% vs. 25%). Two-year brain recurrence was also lower (3.5% vs. 6.6%, p = 0.046). Overall pCR was independently associated with improved DFS in both cohorts, as were immune-related adverse events (irAEs) in NAC + P. In this real-world setting, NAC + P was associated with substantially lower 2-year DR, though the central nervous system remained a common site of recurrence. Beyond pathologic response, the development of irAEs may offer a treatment-specific marker of benefit.

Authors

Institutions

Publication Details

Journal
npj Breast Cancer
Published
2026-11-18
DOI
https://doi.org/10.1038/s41523-026-01070-4
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world rates and sites of recurrence after neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer

Nour K. Abuhadra, Giacomo Montagna, Rachel Han, Lauren M. Perry et al.
5 links
npj Breast Cancer
Breast Cancer Treatment Studies
article

Real-world rates and sites of recurrence after neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer

Nour K. Abuhadra, Giacomo Montagna, Rachel Han, Lauren M. Perry, Marisa Lazarus, Lior Zvi Braunstein, Stephanie Downs‐Canner, Varadan Sevilimedu, Nicholas Mai, Hannah Yong Wen, Monica Morrow, George Plitas, Ellen Yang, Hanna Kissane
article en

Abstract

Neoadjuvant chemoimmunotherapy (NAC + P) improves pathologic complete response (pCR) and survival in early-stage triple-negative breast cancer (TNBC) compared to neoadjuvant chemotherapy (NAC) alone. Real-world recurrence outcomes outside the trial setting remain unclear. This single-institution analysis compared two cohorts of patients with early-stage TNBC treated between July 2009 and April 2023: NAC + P ( n = 344) and NAC ( n = 513). Primary outcomes were local (LR), regional (RR), and distant recurrence (DR); secondary outcomes were DR sites and disease-free survival (DFS). The NAC + P cohort presented with less advanced disease at diagnosis. Overall pCR was higher in NAC + P (58% vs. 36%, p < 0.001). Two-year LR and RR rates did not differ. The 2-year DR rate was nearly halved in NAC + P (9.6% vs. 18%, p < 0.001) and remained lower among patients with residual disease (16% vs. 25%). Two-year brain recurrence was also lower (3.5% vs. 6.6%, p = 0.046). Overall pCR was independently associated with improved DFS in both cohorts, as were immune-related adverse events (irAEs) in NAC + P. In this real-world setting, NAC + P was associated with substantially lower 2-year DR, though the central nervous system remained a common site of recurrence. Beyond pathologic response, the development of irAEs may offer a treatment-specific marker of benefit.

npj Breast Cancer
Memorial Sloan Kettering Cancer Center (US)
Memorial Sloan-Kettering Cancer Center, National Institutes of Health, National Cancer Institute
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon